Trial population
Between December 25 and 29, 2023, a total of 357 participants were screened, of whom 301 were randomly allocated to receive either LZ901 vaccine or HZ/su vaccine. One participant in HZ/su group withdrew from the study before…
Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial
